Lexicon Pharmaceuticals Inc (LXRX)
$0.81 -$0.07 (-8.26%) 4:37 PM 12/14/24
NASDAQ | $USD | BiotechnologyStock Data
-
Market Cap
$254.89M -
Day's Range
$0.75 - $0.83 -
Volume
4,767,901 -
52 Week Low / High
$0.62 - $3.73 -
PE Ratio
- -
PEG Ratio
-0.14 -
Dividend Frequency
-
- Capital Growth
- Dividend Return to Date
- Dividend Payout year Est.
- Expenses
- Total Return
- Total Return %
- 2
- Strong Buy
- 2
- Buy
- 2
- Hold
- 0
- Sell
- 0
- Strong Sell
- $5.55
- Target Price
Company News
-
Lexicon Announces Exclusive Licensing Agreement With Viatris for Sotagliflozin in All Markets Outside of the U.S. and Europe — Oct 16th, 2024
Lexicon Pharmaceuticals, Inc. -Lexicon to receive an upfront payment of $25 million and the potential for contingent regulatory and commercial milestone payments THE WOODLANDS, Texas, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Viat...
-
3 Under-the-Radar Stocks With 340% to 762% Upside in 2024, According to Select Wall Street Analysts — Jan 31st, 2024
Over the long run, Wall Street has proved to be a surefire wealth creator. But over shorter periods, the performance of the major stock indexes is unpredictable. Since this decade began, the Dow Jones Industrial Average, S&P 500, and Nasdaq Composite have traded off bear and bull markets o...
-
Viatris Announces Exclusive Licensing Agreement with Lexicon Pharmaceuticals for Sotagliflozin in all Markets Outside of the U.S. and Europe — Oct 16th, 2024
Continues to Expand Viatris' Innovative Portfolio in Cardiovascular Diseases Leverages Viatris' Unique Global Infrastructure and Expertise Includes Opportunities to Leverage the Potential of Sotagliflozin to Additional Indications PITTSBURGH, Oct. 16, 2024 /PRNewswire/ -- Viatris Inc....
-
Viatris Announces Exclusive Licensing Agreement with Lexicon Pharmaceuticals for Sotagliflozin in all Markets Outside of the U.S. and Europe — Oct 16th, 2024
Continues to Expand Viatris' Innovative Portfolio in Cardiovascular Diseases Leverages Viatris' Unique Global Infrastructure and Expertise Includes Opportunities to Leverage the Potential of Sotagliflozin to Additional Indications PITTSBURGH, Oct. 16, 2024 /PRNewswire/ -- Viatris Inc....
-
Viatris Announces Exclusive Licensing Agreement with Lexicon Pharmaceuticals for Sotagliflozin in all Markets Outside of the U.S. and Europe — Oct 16th, 2024
Continues to Expand Viatris' Innovative Portfolio in Cardiovascular Diseases Leverages Viatris' Unique Global Infrastructure and Expertise Includes Opportunities to Leverage the Potential of Sotagliflozin to Additional Indications PITTSBURGH, Oct. 16, 2024 /PRNewswire/ -- Viatris Inc....
-
Lexicon Announces Exclusive Licensing Agreement With Viatris for Sotagliflozin in All Markets Outside of the U.S. and Europe — Oct 16th, 2024
Lexicon Pharmaceuticals, Inc. -Lexicon to receive an upfront payment of $25 million and the potential for contingent regulatory and commercial milestone payments THE WOODLANDS, Texas, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Viat...
-
Lexicon Announces Exclusive Licensing Agreement With Viatris for Sotagliflozin in All Markets Outside of the U.S. and Europe — Oct 16th, 2024
Lexicon Pharmaceuticals, Inc. -Lexicon to receive an upfront payment of $25 million and the potential for contingent regulatory and commercial milestone payments THE WOODLANDS, Texas, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Viat...
-
Viatris Announces Exclusive Licensing Agreement with Lexicon Pharmaceuticals for Sotagliflozin in all Markets Outside of the U.S. and Europe — Oct 16th, 2024
Continues to Expand Viatris' Innovative Portfolio in Cardiovascular Diseases Leverages Viatris' Unique Global Infrastructure and Expertise Includes Opportunities to Leverage the Potential of Sotagliflozin to Additional Indications PITTSBURGH, Oct. 16, 2024 /PRNewswire/ -- Viatris Inc....
-
Viatris Announces Exclusive Licensing Agreement with Lexicon Pharmaceuticals for Sotagliflozin in all Markets Outside of the U.S. and Europe — Oct 16th, 2024
Continues to Expand Viatris' Innovative Portfolio in Cardiovascular Diseases Leverages Viatris' Unique Global Infrastructure and Expertise Includes Opportunities to Leverage the Potential of Sotagliflozin to Additional Indications PITTSBURGH, Oct. 16, 2024 /PRNewswire/ -- Viatris Inc....
-
Lexicon Announces Exclusive Licensing Agreement With Viatris for Sotagliflozin in All Markets Outside of the U.S. and Europe — Oct 16th, 2024
Lexicon Pharmaceuticals, Inc. -Lexicon to receive an upfront payment of $25 million and the potential for contingent regulatory and commercial milestone payments THE WOODLANDS, Texas, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Viat...
-
Lexicon Announces Exclusive Licensing Agreement With Viatris for Sotagliflozin in All Markets Outside of the U.S. and Europe — Oct 16th, 2024
Lexicon Pharmaceuticals, Inc. -Lexicon to receive an upfront payment of $25 million and the potential for contingent regulatory and commercial milestone payments THE WOODLANDS, Texas, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Viat...
-
Lexicon Announces Exclusive Licensing Agreement With Viatris for Sotagliflozin in All Markets Outside of the U.S. and Europe — Oct 16th, 2024
Lexicon Pharmaceuticals, Inc. -Lexicon to receive an upfront payment of $25 million and the potential for contingent regulatory and commercial milestone payments THE WOODLANDS, Texas, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Viat...
-
Lexicon Announces Exclusive Licensing Agreement With Viatris for Sotagliflozin in All Markets Outside of the U.S. and Europe — Oct 16th, 2024
Lexicon Pharmaceuticals, Inc. -Lexicon to receive an upfront payment of $25 million and the potential for contingent regulatory and commercial milestone payments THE WOODLANDS, Texas, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Viat...
-
Viatris Announces Exclusive Licensing Agreement with Lexicon Pharmaceuticals for Sotagliflozin in all Markets Outside of the U.S. and Europe — Oct 16th, 2024
Continues to Expand Viatris' Innovative Portfolio in Cardiovascular Diseases Leverages Viatris' Unique Global Infrastructure and Expertise Includes Opportunities to Leverage the Potential of Sotagliflozin to Additional Indications PITTSBURGH, Oct. 16, 2024 /PRNewswire/ -- Viatris Inc....
-
Lexicon Announces Exclusive Licensing Agreement With Viatris for Sotagliflozin in All Markets Outside of the U.S. and Europe — Oct 16th, 2024
Lexicon Pharmaceuticals, Inc. -Lexicon to receive an upfront payment of $25 million and the potential for contingent regulatory and commercial milestone payments THE WOODLANDS, Texas, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Viat...
-
Viatris Announces Exclusive Licensing Agreement with Lexicon Pharmaceuticals for Sotagliflozin in all Markets Outside of the U.S. and Europe — Oct 16th, 2024
Continues to Expand Viatris' Innovative Portfolio in Cardiovascular Diseases Leverages Viatris' Unique Global Infrastructure and Expertise Includes Opportunities to Leverage the Potential of Sotagliflozin to Additional Indications PITTSBURGH, Oct. 16, 2024 /PRNewswire/ -- Viatris Inc....
-
Viatris Announces Exclusive Licensing Agreement with Lexicon Pharmaceuticals for Sotagliflozin in all Markets Outside of the U.S. and Europe — Oct 16th, 2024
Continues to Expand Viatris' Innovative Portfolio in Cardiovascular Diseases Leverages Viatris' Unique Global Infrastructure and Expertise Includes Opportunities to Leverage the Potential of Sotagliflozin to Additional Indications PITTSBURGH, Oct. 16, 2024 /PRNewswire/ -- Viatris Inc....
Portfolio
Comprised of 1 portfolios